A comparative proteomics pipeline and the first CRISPR-Cas9 gene editing in Fasciola hepatica juveniles have identified three ...
A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...
NEW ORLEANS, LA—An investigational CRISPR-Cas9 gene-editing therapy that targets angiopoietin-like protein 3 (ANGPTL3), which has a role in regulating lipid metabolism, appears to safely lower levels ...
The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...
CRSP’s main value driver is Casgevy, which was approved for sickle cell disease and β-thalassemia. It’s a one-time ex vivo CRISPR/Cas9 stem‐cell therapy. Unfortunately, Casgevy’s rollout has been slow ...
A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...
Emerging gene-editing platforms are demonstrating that disease-causing mutations, aberrant gene expression, and even large-scale DNA insertions can be corrected without relying on error-prone DNA ...
Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results